Ohio Living Rockynol in Akron, OH

Ohio Living Rockynol is a medicare and medicaid certified nursing home in Akron, Ohio. It is located in Summit county at 1150 W Market St, Akron, Ohio 44313. You can reach out to the office of Ohio Living Rockynol via phone at (330) 867-2150. This skilled nursing facility has 74 federally certified beds with average occupancy rate of 79.59%. The nursing facility is classified as "Continuing Care Retirement Community" by CMS and its legal business name is Ohio Living Communities and has the following ownership type - Non Profit - Corporation.

Ohio Living Rockynol (Medicare CCN 365051) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in both medicare and medicaid program. This means if you are part of medicare or medicaid program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 1967 (57 years certified) and the last quality survey was conducted in April, 2019.

Name	Ohio Living Rockynol
Location	1150 W Market St, Akron, Ohio
Certified By	Medicare and Medicaid
No. of Certified Beds	74
Occupancy Rate	79.59%
Medicare ID (CCN)	365051
Legal Business Name	Ohio Living Communities
Ownership Type	Non Profit - Corporation

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Ohio Living Rockynol from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number	1366438368
Organization Name	OHIO LIVING COMMUNITIES
Doing Business As	OHIO LIVING ROCKYNOL
Address	1150 W Market St, Akron, OH 44313
Phone Number	330-867-2150

News Archive

Gestational diabetes may increase offspring's heart disease risk

Gestational diabetes may increase the risk of blood vessel dysfunction and heart disease in offspring by altering a smooth muscle protein responsible for blood vessel network formation.

New computational method can help predict and design allosteric functions in proteins

Called the "second secret of life", allostery is one of the most fundamental processes of biology and has been a central focus among scientists across the life sciences spectrum, from fundamental biology to drug development.

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.

Data from GenVec's trial in esophageal cancer showcased at 2010 Gastrointestinal Cancer Symposium

GenVec, Inc. announced today that data from the Company's trial in esophageal cancer were presented at the American Society of Clinical Oncology's 2010 Gastrointestinal Cancer Symposium in Orlando, Florida on January 22, 2010.

Read more Medical News

› Verified 9 days ago

Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Ohio Living Rockynol are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Ohio Living Rockynol give to their patients.

Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

Gestational diabetes may increase offspring's heart disease risk

Gestational diabetes may increase the risk of blood vessel dysfunction and heart disease in offspring by altering a smooth muscle protein responsible for blood vessel network formation.

New computational method can help predict and design allosteric functions in proteins

Called the "second secret of life", allostery is one of the most fundamental processes of biology and has been a central focus among scientists across the life sciences spectrum, from fundamental biology to drug development.

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.

Data from GenVec's trial in esophageal cancer showcased at 2010 Gastrointestinal Cancer Symposium

GenVec, Inc. announced today that data from the Company's trial in esophageal cancer were presented at the American Society of Clinical Oncology's 2010 Gastrointestinal Cancer Symposium in Orlando, Florida on January 22, 2010.

Read more Medical News

› Verified 9 days ago

Number of Facility Reported Incidents	0
Number of Substantiated Complaints	0
Number of Fines	2
Total Amount of Fines in Dollars	$1625
Number of Payment Denials	0
Total Number of Penalties	2

The resident survey data of Ohio Living Rockynol is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience Measure	Provider	National Avg.
Percentage of long-stay residents whose need for help with daily activities has increased	29.11	14.46
Percentage of long-stay residents who lose too much weight	9.2	5.51